P/E ratio for Royalty Pharma (RPRX)
P/E ratio as of April 2024 (TTM): 50.9
According to Royalty Pharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 50.8727. At the end of 2022 the company had a P/E ratio of 395.
P/E ratio history for Royalty Pharma from 2020 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 395 | 1387.58% |
| 2021 | 26.6 | -19.3% |
| 2020 | 32.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | 36.0 | -29.31% | 🇺🇸 USA |
 Eli Lilly LLY | 135 | 165.10% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | -139 | -373.65% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.